Instituto Rosenbusch
Market Cap
AR$430.2m
Last Updated
2021/02/25 22:03 UTC
Data Sources
Company Financials
Executive Summary
Instituto Rosenbusch S.A. researches, develops, manufactures, and sells veterinary products in Argentina. More Details
Risk Analysis
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Instituto Rosenbusch's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ROSE is more volatile than 90% of AR stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ROSE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of AR stocks.
Market Performance
7 Day Return
-8.2%
ROSE
-0.9%
AR Pharmaceuticals
-3.4%
AR Market
1 Year Return
88.8%
ROSE
-2.3%
AR Pharmaceuticals
25.8%
AR Market
Return vs Industry: ROSE exceeded the AR Pharmaceuticals industry which returned -5.2% over the past year.
Return vs Market: ROSE exceeded the AR Market which returned 14.3% over the past year.
Shareholder returns
| ROSE | Industry | Market | |
|---|---|---|---|
| 7 Day | -8.2% | -0.9% | -3.4% |
| 30 Day | -13.7% | -2.1% | -1.5% |
| 90 Day | -13.7% | 6.2% | -12.8% |
| 1 Year | 88.8%88.8% | 0.4%-2.3% | 26.5%25.8% |
| 3 Year | 22.9%22.9% | 11.6%3.1% | 32.9%24.5% |
| 5 Year | 129.5%129.5% | 43.6%25.9% | 195.3%158.7% |
Long-Term Price Volatility Vs. Market
How volatile is Instituto Rosenbusch's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Instituto Rosenbusch undervalued compared to its fair value and its price relative to the market?
3.42x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ROSE (ARS10.1) is trading above our estimate of fair value (ARS0.55)
Significantly Below Fair Value: ROSE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ROSE is unprofitable, so we can't compare its PE Ratio to the XX Pharmaceuticals industry average.
PE vs Market: ROSE is unprofitable, so we can't compare its PE Ratio to the AR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ROSE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ROSE is overvalued based on its PB Ratio (3.4x) compared to the XS Pharmaceuticals industry average (3.3x).
Next Steps
Future Growth
How is Instituto Rosenbusch forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Instituto Rosenbusch has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Instituto Rosenbusch's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Instituto Rosenbusch performed over the past 5 years?
-49.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ROSE is currently unprofitable.
Growing Profit Margin: ROSE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ROSE is unprofitable, and losses have increased over the past 5 years at a rate of 49.7% per year.
Accelerating Growth: Unable to compare ROSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ROSE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.4%).
Return on Equity
High ROE: ROSE has a negative Return on Equity (2.13%), as it is currently unprofitable.
Next Steps
Financial Health
How is Instituto Rosenbusch's financial position?
Financial Position Analysis
Short Term Liabilities: ROSE's short term assets (ARS470.9M) exceed its short term liabilities (ARS440.4M).
Long Term Liabilities: ROSE's short term assets (ARS470.9M) exceed its long term liabilities (ARS19.6M).
Debt to Equity History and Analysis
Debt Level: ROSE's debt to equity ratio (104.3%) is considered high.
Reducing Debt: ROSE's debt to equity ratio has increased from 34.8% to 104.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ROSE has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ROSE is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 31.7% per year.
Next Steps
Dividend
What is Instituto Rosenbusch current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ROSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ROSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ROSE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ROSE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ROSE's dividend in 3 years as they are not forecast to pay a notable one for the AR market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Rodolfo Martín Balestrini
no data
Tenure
Dr. Rodolfo Martín Balestrini serves as the President of Instituto Rosenbusch S.A. Dr. Balestrini serves as Chairman of the Board of Directors at Instituto Rosenbusch S.A.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Instituto Rosenbusch S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Instituto Rosenbusch S.A.
- Ticker: ROSE
- Exchange: BASE
- Founded: 1917
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AR$430.154m
- Shares outstanding: 42.59m
- Website: https://www.rosenbusch.com
Location
- Instituto Rosenbusch S.A.
- Hipólito Yrigoyen 1628 (C1089AAF)
- Buenos Aires
- 1136
- Argentina
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ROSE | BASE (Buenos Aires Stock Exchange) | Yes | Class B Common Stock | AR | ARS | Sep 1999 |
Biography
Instituto Rosenbusch S.A. researches, develops, manufactures, and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory and nervous...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/25 22:03 |
| End of Day Share Price | 2021/02/23 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.